Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Mark Verdecia, John F. Kokai-Kun, Maura Kibbey, Sarita Acharya, Jaap Venema & Fouad Atouf. (2021) COVID-19 vaccine platforms: Delivering on a promise?. Human Vaccines & Immunotherapeutics 17:9, pages 2873-2893.
Read now
Read now
Minxi Wei, Daning Wang, Zhihai Li, Shuo Song, Xianglin Kong, Xiaobing Mo, Yurou Yang, Maozhou He, Zhongyi Li, Bo Huang, Zhijie Lin, Huirong Pan, Qingbing Zheng, Hai Yu, Ying Gu, Jun Zhang, Shaowei Li & Ningshao Xia. (2018) N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro. Emerging Microbes & Infections 7:1, pages 1-12.
Read now
Read now
Xiao Zhang, Lu Xin, Shaowei Li, Mujin Fang, Jun Zhang, Ningshao Xia & Qinjian Zhao. (2015) Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Human Vaccines & Immunotherapeutics 11:5, pages 1277-1292.
Read now
Read now
Yue Zhang, Min Li, Fan Yang, Yufang Li, Zizheng Zheng, Xiao Zhang, Qingshan Lin, Ying Wang, Shaowei Li, Ningshao Xia, Jun Zhang & Qinjian Zhao. (2015) Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment. Human Vaccines & Immunotherapeutics 11:5, pages 1129-1139.
Read now
Read now
Hongjing Gu, Tieling Li, Lina Han, Ping Zhu, Peirui Zhang, Shaogeng Zhang, Sujing Sun, Yueqiang Duan, Li Xing, Zhongpeng Zhao, Chengcai Lai, Bohai Wen, Xiliang Wang & PengHui Yang. (2015) Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination . Human Vaccines & Immunotherapeutics 11:4, pages 1057-1064.
Read now
Read now
Shao-Wei Li, Qinjian Zhao, Ting Wu, Shu Chen, Jun Zhang & Ning-Shao Xia. (2015) The development of a recombinant hepatitis E vaccine HEV 239. Human Vaccines & Immunotherapeutics 11:4, pages 908-914.
Read now
Read now
Barbara Romanowski, Tino F Schwarz, Linda M Ferguson, Murdo Ferguson, Klaus Peters, Marc Dionne, Karin Schulze, Brian Ramjattan, Peter Hillemanns, Ulrich Behre, Pemmaraju Suryakiran, Florence Thomas & Frank Struyf. (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Human Vaccines & Immunotherapeutics 10:5, pages 1155-1165.
Read now
Read now
Qinjian Zhao, Clinton S Potter, Bridget Carragher, Gabriel Lander, Jaime Sworen, Victoria Towne, Dicky Abraham, Paul Duncan, Michael W Washabaugh & Robert D Sitrin. (2014) Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. Human Vaccines & Immunotherapeutics 10:3, pages 734-739.
Read now
Read now
Brooke E Hjelm, Jacquelyn Kilbourne & Melissa M Herbst-Kralovetz. (2014) TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Human Vaccines & Immunotherapeutics 10:2, pages 410-416.
Read now
Read now
Fabiana Fernandes, Ana P Teixeira, Nuno Carinhas, Manuel JT Carrondo & Paula M Alves. (2013) Insect cells as a production platform of complex virus-like particles. Expert Review of Vaccines 12:2, pages 225-236.
Read now
Read now
Jimmy A Mena & Amine A Kamen. (2011) Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Review of Vaccines 10:7, pages 1063-1081.
Read now
Read now
Nathalie Garçon & Marcelle Van Mechelen. (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Review of Vaccines 10:4, pages 471-486.
Read now
Read now
Peter Hillemanns. (2011) Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324–38. Journal of Medical Economics 14:2, pages 262-266.
Read now
Read now
Stephen Hearty, Paul J Conroy, B Vijayalakshmi Ayyar, Barry Byrne & Richard O’Kennedy. (2010) Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Review of Vaccines 9:6, pages 645-664.
Read now
Read now
Articles from other publishers (93)
Sangiliyandi Gurunathan, Pratheep Thangaraj, Lin Wang, Qilong Cao & Jin-Hoi Kim. (2024) Nanovaccines: An effective therapeutic approach for cancer therapy. Biomedicine & Pharmacotherapy 170, pages 115992.
Crossref
Crossref
Yu-Ling Chen, Chun-Jie Bao, Jia-Lun Duan, Ying Xie & Wan-Liang Lu. (2023) Overcoming biological barriers by virus-like drug particles for drug delivery. Advanced Drug Delivery Reviews 203, pages 115134.
Crossref
Crossref
Mei Dang, Long J. Wu, Si R. Zhang, Jian R. Zhu, Yu Z. Hu, Chen X. Yang & Xiao Y. Zhang. (2023) MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths. ACS Synthetic Biology.
Crossref
Crossref
Marko Popovic. (2023) The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants. Microbial Risk Analysis 23, pages 100249.
Crossref
Crossref
Gang Zhang, Pu Wang, Lingling Jiang, Sheng Wang, Sinong Zhang & Yong Li. (2023) Evaluation of the immunogenicity of vaccine candidates developed using a baculovirus surface display system for Crimean-Congo hemorrhagic fever virus in mice. Frontiers in Microbiology 14.
Crossref
Crossref
Durjoy Majumder. (2023) Mathematical Oncology to Cancer Systems Medicine: Translation from
Academic Pursuit to Individualized Therapy with MORA. Current Cancer Therapy Reviews 19:1, pages 37-57.
Crossref
Crossref
Marko Popovic. (2022) Biothermodynamics of Viruses from Absolute Zero (1950) to Virothermodynamics (2022). Vaccines 10:12, pages 2112.
Crossref
Crossref
Kaushal Jerajani, Ying Wan, John M. Hickey, Ozan S. Kumru, Nitya Sharma, Swathi R. Pullagurla, Oluwadara Ogun, Shweta Mapari, Neal Whitaker, Sarah Brendle, Neil D. Christensen, Saurabh Batwal, Mustafa Mahedvi, Harish Rao, Vikas Dogar, Rahul Chandrasekharan, Umesh Shaligram, Sangeeta B. Joshi & David B. Volkin. (2022) Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development. Journal of Pharmaceutical Sciences 111:11, pages 2983-2997.
Crossref
Crossref
Aliyu Maje Bello & Yaowaluck Maprang Roshorm. (2022) Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD). Biologicals 79, pages 1-9.
Crossref
Crossref
Flávia M. Corrêa, Arn Migowski, Liz M. de Almeida & Marcelo A. Soares. (2022) Cervical cancer screening, treatment and prophylaxis in Brazil: Current and future perspectives for cervical cancer elimination. Frontiers in Medicine 9.
Crossref
Crossref
Xingliang Fang, Huanrong Lan, Ketao Jin, Daojun Gong & Jun Qian. (2022) Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review. Cancers 14:16, pages 3842.
Crossref
Crossref
Annamalai RamaAnuja PaiDivya Rosa BarretoSiva Kumar KannanAnup Naha. (2022) Virus-Like particles as a Novel Targeted Drug Delivery Platform for Biomedical Applications. Research Journal of Pharmacy and Technology, pages 2801-2808.
Crossref
Crossref
Steven F. Gameiro, Andris M. Evans & Joe S. Mymryk. (2021)
The tumor immune microenvironments of
HPV
+
and
HPV
−
head and neck cancers
. WIREs Mechanisms of Disease 14:2.
Crossref
Crossref
Jianming Tang, Mingzhu Li, Chao Zhao, Danhua Shen, Lei Liu, Xiujun Zhang & Lihui Wei. (2022) Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials. Viruses 14:2, pages 239.
Crossref
Crossref
Zhanhui Wang, Mengyao Liu, Haoran Zhao, Pengpeng Wang, Wenge Ma, Yunke Zhang, Wenxue Wu & Chen Peng. (2021) Induction of Robust and Specific Humoral and Cellular Immune Responses by Bovine Viral Diarrhea Virus Virus-Like Particles (BVDV-VLPs) Engineered with Baculovirus Expression Vector System. Vaccines 9:4, pages 350.
Crossref
Crossref
Ning Li, Gaiping Zhang, Yumei Chen, Jingming Zhou, Cui Hui, Shuo Li, Hongliang Liu, Yankai Liu, Yanhua Qi & Aiping Wang. (2021) Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies. International Journal of Biological Macromolecules 174, pages 587-595.
Crossref
Crossref
Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, Camellia Katalani, Abbas Hajizade, Andrew J. Easton & Gholamreza Ahmadian. (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Arnaud John Kombe Kombe, Bofeng Li, Ayesha Zahid, Hylemariam Mihiretie Mengist, Guy-Armel Bounda, Ying Zhou & Tengchuan Jin. (2021) Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Frontiers in Public Health 8.
Crossref
Crossref
Susan Krueger, Joseph E. Curtis, Daniel R. Scott, Alexander Grishaev, Greg Glenn, Gale Smith, Larry Ellingsworth, Oleg Borisov & Ernest L. Maynard. (2020) Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution. Molecular Pharmaceutics 18:1, pages 359-376.
Crossref
Crossref
So Hwa Kim, Young Chan Park & Jae Min Song. (2021) Evaluation of the antigenic stability of influenza virus like particles after exposure to acidic or basic pH. Clinical and Experimental Vaccine Research 10:3, pages 252.
Crossref
Crossref
Kyle Saylor, Alison Waldman, Frank Gillam & Chenming Zhang. (2020) Multi-epitope insert modulates solubility-based and chromatographic purification of human papilloma virus 16 L1-based vaccine without inhibiting virus-like particle assembly. Journal of Chromatography A 1631, pages 461567.
Crossref
Crossref
Amin Azimi, Sheida Heidarian, Homa Zamani, Nastaran Taleghani, Mohsen Dehghani & Ehsan Seyedjafari. (2020) Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine. Biologicals 68, pages 60-64.
Crossref
Crossref
Yanli Yang, Zhiguo Su, Guanghui Ma & Songping Zhang. (2020) Characterization and stabilization in process development and product formulation for super large proteinaceous particles. Engineering in Life Sciences 20:11, pages 451-465.
Crossref
Crossref
Annalisa Colaprico, Silvia Senesi, Francesca Ferlicca, Brunella Brunelli, Mildred Ugozzoli, Michele Pallaoro & Derek T. O'Hagan. (2020) Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. Vaccine 38:19, pages 3600-3609.
Crossref
Crossref
Ciying Qian, Xinlin Liu, Qin Xu, Zhiping Wang, Jie Chen, Tingting Li, Qingbing Zheng, Hai Yu, Ying Gu, Shaowei Li & Ningshao Xia. (2020) Recent Progress on the Versatility of Virus-Like Particles. Vaccines 8:1, pages 139.
Crossref
Crossref
Vaneet Kumar Sharma, Ity Sharma & James Glick. (2018) The expanding role of mass spectrometry in the field of vaccine development. Mass Spectrometry Reviews 39:1-2, pages 83-104.
Crossref
Crossref
Mehdi kheirollahpour, Mohsen Mehrabi, Naser Mohammadpour Dounighi, Mohsen Mohammadi & Alireza Masoudi. (2020) Nanoparticles and Vaccine Development. Pharmaceutical Nanotechnology 8:1, pages 6-21.
Crossref
Crossref
Bárbara Fernandes, João Vidigal, Ricardo Correia, Manuel J.T. Carrondo, Paula M. Alves, Ana P. Teixeira & António Roldão. (2020) Adaptive laboratory evolution of stable insect cell lines for improved HIV-Gag VLPs production. Journal of Biotechnology 307, pages 139-147.
Crossref
Crossref
Chen Hua, Yun Zhu, Congquan Wu, Lulu Si, Qian Wang, Long Sui & Shibo Jiang. (2019) The Underlying Mechanism of 3-Hydroxyphthalic Anhydride-Modified Bovine Beta-Lactoglobulin to Block Human Papillomavirus Entry Into the Host Cell. Frontiers in Microbiology 10.
Crossref
Crossref
Ina Balke & Andris Zeltins. (2019) Use of plant viruses and virus-like particles for the creation of novel vaccines. Advanced Drug Delivery Reviews 145, pages 119-129.
Crossref
Crossref
Xilin Wu, Xiaohua Ma, Yanlei Li, Yue Xu, Nan Zheng, Shijie Xu, Waqas Nawaz & Zhiwei Wu. (2019) Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells. Antibody Therapeutics.
Crossref
Crossref
Ali Ghasemi, Ali Bozorg, Farzaneh Rahmati, Reihaneh Mirhassani & Saman Hosseininasab. (2019) Comprehensive study on Wave bioreactor system to scale up the cultivation of and recombinant protein expression in baculovirus-infected insect cells. Biochemical Engineering Journal 143, pages 121-130.
Crossref
Crossref
Eduardo Lazcano-Ponce, Leticia Torres-Ibarra, Aurelio Cruz-Valdez, Jorge Salmerón, Tonatiuh Barrientos-Gutiérrez, Javier Prado-Galbarro, Margaret Stanley, Nubia Muñoz, Rolando Herrero & Mauricio Hernández-Ávila. (2019) Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. The Journal of Infectious Diseases 219:1, pages 41-49.
Crossref
Crossref
Zoltán Kis, Robin Shattock, Nilay Shah & Cleo Kontoravdi. (2018) Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture. Biotechnology Journal 14:1.
Crossref
Crossref
Zhihai Li, Shuo Song, Maozhou He, Daning Wang, Jingjie Shi, Xinlin Liu, Yunbing Li, Xin Chi, Shuangping Wei, Yurou Yang, Zhiping Wang, Jinjin Li, Huilian Qian, Hai Yu, Qingbing Zheng, Xiaodong Yan, Qinjian Zhao, Jun Zhang, Ying Gu, Shaowei Li & Ningshao Xia. (2018) Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications 9:1.
Crossref
Crossref
Helba Bredell, Jacques J. Smith, Johann F. Görgens & Willem H. van Zyl. (2018)
Expression of unique chimeric human papilloma virus type 16 (HPV-16) L1-L2 proteins in
Pichia pastoris
and
Hansenula polymorpha
. Yeast 35:9, pages 519-529.
Crossref
Crossref
Peggy Stolt-Bergner, Christian Benda, Tim Bergbrede, Hüseyin Besir, Patrick H.N. Celie, Cindy Chang, David Drechsel, Ariane Fischer, Arie Geerlof, Barbara Giabbai, Joop van den Heuvel, Georg Huber, Wolfgang Knecht, Anita Lehner, Regis Lemaitre, Kristina Nordén, Gwynn Pardee, Ines Racke, Kim Remans, Astrid Sander, Judith Scholz, Magda Stadnik, Paola Storici, Daniel Weinbruch, Isabel Zaror, Linda H.L. Lua & Sabine Suppmann. (2018) Baculovirus-driven protein expression in insect cells: A benchmarking study. Journal of Structural Biology 203:2, pages 71-80.
Crossref
Crossref
Richard B. S. Roden & Peter L. Stern. (2018) Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Reviews Cancer 18:4, pages 240-254.
Crossref
Crossref
Andris Zeltins. 2018. Virus Protein and Nucleoprotein Complexes. Virus Protein and Nucleoprotein Complexes
379
405
.
Zhihai Li, Daning Wang, Ying Gu, Shuo Song, Maozhou He, Jingjie Shi, Xinlin Liu, Shuangping Wei, Jinjin Li, Hai Yu, Qingbing Zheng, Xiaodong Yan, Timothy S. Baker, Jun Zhang, Jason S. McLellan, Shaowei Li & Ningshao Xia. (2017) Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. mBio 8:5.
Crossref
Crossref
Kendra H. Steele, Barbara J. Stone, Kathleen M. Franklin, Angelika Fath‐Goodin, Xiufeng Zhang, Haobo Jiang, Bruce A. Webb & Christoph Geisler. (2017) Improving the baculovirus expression vector system with vankyrin‐enhanced technology. Biotechnology Progress 33:6, pages 1496-1507.
Crossref
Crossref
Ying Gu, Minxi Wei, Daning Wang, Zhihai Li, Minghui Xie, Huirong Pan, Ting Wu, Jun Zhang, Shaowei Li & Ningshao Xia. (2017) Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine 35:35, pages 4637-4645.
Crossref
Crossref
Dandan Zhao, Bo Sun, Shiyang Sun, Bin Fu, Chuntian Liu, Dawei Liu, Yanfei Chu, Youlei Ma, Lu Bai, Yongge Wu, Yan Zhou, Weiheng Su, Ali Hou, Linjun Cai, Fei Xu, Wei Kong & Chunlai Jiang. (2017) Characterization of human enterovirus71 virus-like particles used for vaccine antigens. PLOS ONE 12:7, pages e0181182.
Crossref
Crossref
Huirong Pan, Zhihai Li, Jin Wang, Shuo Song, Daning Wang, Minxi Wei, Ying Gu, Jun Zhang, Shaowei Li & Ningshao Xia. (2017) Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Vaccine 35:24, pages 3222-3231.
Crossref
Crossref
Michael Martin Pieler, Anja Heyse, Michael Werner Wolff & Udo Reichl. (2017) Specific ion effects on the particle size distributions of cell culture-derived influenza A virus particles within the Hofmeister series. Engineering in Life Sciences 17:5, pages 470-478.
Crossref
Crossref
Xiaofen Huang, Xin Wang, Jun Zhang, Ningshao Xia & Qinjian Zhao. (2017) Escherichia coli-derived virus-like particles in vaccine development. npj Vaccines 2:1.
Crossref
Crossref
Jian Guan, Stephanie M. Bywaters, Sarah A. Brendle, Robert E. Ashley, Alexander M. Makhov, James F. Conway, Neil D. Christensen & Susan Hafenstein. (2017) Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site. Structure 25:2, pages 253-263.
Crossref
Crossref
Bettina Huber, Christina Schellenbacher, Saeed Shafti-Keramat, Christoph Jindra, Neil Christensen & Reinhard Kirnbauer. (2017) Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLOS ONE 12:1, pages e0169533.
Crossref
Crossref
Vivek Verma, Wenzhi Tan, Sao Puth, Kyoung-Oh Cho, Shee Eun Lee & Joon Haeng Rhee. (2016) Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB. Journal of Translational Medicine 14:1.
Crossref
Crossref
John M. Hickey, Neha Sahni, Ronald T. TothIVIV, Ozan S. Kumru, Sangeeta B. Joshi, C. Russell Middaugh & David B. Volkin. (2016) Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms. Journal of Chromatography B 1032, pages 23-38.
Crossref
Crossref
Colleen E. Clancy, Gary An, William R. Cannon, Yaling Liu, Elebeoba E. May, Peter Ortoleva, Aleksander S. Popel, James P. Sluka, Jing Su, Paolo Vicini, Xiaobo Zhou & David M. Eckmann. (2016) Multiscale Modeling in the Clinic: Drug Design and Development. Annals of Biomedical Engineering 44:9, pages 2591-2610.
Crossref
Crossref
Mathieu Boxus, Michel Fochesato, Agnès Miseur, Emmanuel Mertens, Najoua Dendouga, Sarah Brendle, Karla K. Balogh, Neil D. Christensen & Sandra L. Giannini. (2016) Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Journal of Virology 90:14, pages 6314-6325.
Crossref
Crossref
Ming-Kun Liu, Jhe-Jhih Lin, Chung-Yung Chen, Szu-Cheng Kuo, Yu-Ming Wang, Hong-Lin Chan & Tzong Wu. (2016) Topoisomerase II Inhibitors Can Enhance Baculovirus-Mediated Gene Expression in Mammalian Cells through the DNA Damage Response. International Journal of Molecular Sciences 17:6, pages 931.
Crossref
Crossref
Zhihai Li, Xiaodong Yan, Hai Yu, Daning Wang, Shuo Song, Yunbing Li, Maozhou He, Qiyang Hong, Qingbing Zheng, Qinjian Zhao, Ying Gu, Jun Zhang, Mandy?E.W. Janssen, Giovanni Cardone, Norman?H. Olson, Timothy?S. Baker, Shaowei Li & Ningshao Xia. (2016) The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction. Structure 24:6, pages 874-885.
Crossref
Crossref
Ariana Harari, Zigui Chen, Ana Cecilia Rodríguez, Allan Hildesheim, Carolina Porras, Rolando Herrero, Sholom Wacholder, Orestis A. Panagiotou, Brian Befano, Robert D. Burk & Mark Schiffman. (2016) Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. Journal of Infectious Diseases 213:6, pages 939-947.
Crossref
Crossref
Maren Bleckmann, Margitta Schürig, Fang-Fang Chen, Zen-Zen Yen, Nils Lindemann, Steffen Meyer, Johannes Spehr & Joop van den Heuvel. (2016) Identification of Essential Genetic Baculoviral Elements for Recombinant Protein Expression by Transactivation in Sf21 Insect Cells. PLOS ONE 11:3, pages e0149424.
Crossref
Crossref
Christopher Ladd Effio, Stefan A. Oelmeier & Jürgen Hubbuch. (2016) High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography. Vaccine 34:10, pages 1259-1267.
Crossref
Crossref
Xiao Zhang, Shaowei Li, Yorgo Modis, Zhihai Li, Jun Zhang, Ningshao Xia & Qinjian Zhao. (2016) Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Reviews in Medical Virology 26:2, pages 115-128.
Crossref
Crossref
Virginie Bettonville, Jérôme T. J. Nicol, Nicolas Thelen, Marc Thiry, Marianne Fillet, Nathalie Jacobs & Anne-Catherine Servais. (2016) Study of intact virus-like particles of human papillomavirus by capillary electrophoresis. ELECTROPHORESIS 37:4, pages 579-586.
Crossref
Crossref
Thomas A. Kost & Christopher W. Kemp. 2016. Advanced Technologies for Protein Complex Production and Characterization. Advanced Technologies for Protein Complex Production and Characterization
187
197
.
Tamer Z. Salem, Craig P. Seaborn, Colin M. Turney, Jianli Xue, Hui Shang & Xiao-Wen Cheng. (2015) The Influence of SV40 polyA on Gene Expression of Baculovirus Expression Vector Systems. PLOS ONE 10:12, pages e0145019.
Crossref
Crossref
Jian Guan, Stephanie M. Bywaters, Sarah A. Brendle, Hyunwook Lee, Robert E. Ashley, Neil D. Christensen & Susan Hafenstein. (2015) The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. Journal of Virology 89:23, pages 12108-12117.
Crossref
Crossref
Lawrence Segal, Danielle Morelle, Kari Kaaber, Eric Destexhe & Nathalie Garçon. (2015) Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats. Journal of Applied Toxicology 35:12, pages 1577-1585.
Crossref
Crossref
Andrew Abi Mansour, Yuriy V. Sereda, Jing Yang & Peter J. Ortoleva. (2015) Prospective on multiscale simulation of virus-like particles: Application to computer-aided vaccine design. Vaccine 33:44, pages 5890-5896.
Crossref
Crossref
Jian Guan, Stephanie M. Bywaters, Sarah A. Brendle, Hyunwook Lee, Robert E. Ashley, Alexander M. Makhov, James F. Conway, Neil D. Christensen & Susan Hafenstein. (2015) Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology 483, pages 253-263.
Crossref
Crossref
Shujing Wang, Huiqin Liu, Xinyi Zhang & Feng Qian. (2015) Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein & Cell 6:7, pages 480-503.
Crossref
Crossref
Rachael S. Felberbaum. (2015) The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnology Journal 10:5, pages 702-714.
Crossref
Crossref
Balaji Somasundaram & Linda HL Lua. (2015) Development of picornavirus-like particle vaccines. Pharmaceutical Bioprocessing 3:1, pages 45-59.
Crossref
Crossref
Robert D. Sitrin, Qinjian Zhao, Clinton S. Potter, Bridget Carragher & Michael W. Washabaugh. 2015. Vaccine Analysis: Strategies, Principles, and Control. Vaccine Analysis: Strategies, Principles, and Control
81
112
.
Ana Gabriela Leija-MontoyaMaría Luisa Benítez-HessJulia Dolores Toscano-GaribayLuis Marat Alvarez-Salas. (2014) Characterization of an RNA Aptamer Against HPV-16 L1 Virus-Like Particles. Nucleic Acid Therapeutics 24:5, pages 344-355.
Crossref
Crossref
Annandita Kumar, Taylor Jacob, Cynthia Y. Abban & Patricio I. Meneses. (2014) Intermediate Heparan Sulfate Binding During HPV-16 Infection in HaCaTs. American Journal of Therapeutics 21:5, pages 331-342.
Crossref
Crossref
Johan M. J. Van den Bergh, Khadija Guerti, Yannick Willemen, Eva Lion, Nathalie Cools, Herman Goossens, Alex Vorsters, Viggo F. I. Van Tendeloo, Sébastien Anguille, Pierre Van Damme & Evelien L. J. M. Smits. (2014)
HPV
vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against
HPV
‐positive tumour cells
. Journal of Cellular and Molecular Medicine 18:7, pages 1372-1380.
Crossref
Crossref
Xiao Zhang, Minxi Wei, Huirong Pan, Zhijie Lin, Kaihang Wang, Zusen Weng, Yibin Zhu, Lu Xin, Jun Zhang, Shaowei Li, Ningshao Xia & Qinjian Zhao. (2014) Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®. Vaccine 32:32, pages 4039-4050.
Crossref
Crossref
Linda H.L. Lua, Natalie K. Connors, Frank Sainsbury, Yap P. Chuan, Nani Wibowo & Anton P.J. Middelberg. (2014) Bioengineering virus-like particles as vaccines. Biotechnology and Bioengineering 111:3, pages 425-440.
Crossref
Crossref
Eduardo Lazcano-Ponce, Margaret Stanley, Nubia Muñoz, Leticia Torres, Aurelio Cruz-Valdez, Jorge Salmerón, Rosalba Rojas, Rolando Herrero & Mauricio Hernández-Ávila. (2014) Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32:6, pages 725-732.
Crossref
Crossref
Stephen J. Streatfield, Natasha Kushnir & Vidadi Yusibov. 2014. Commercial Plant-Produced Recombinant Protein Products. Commercial Plant-Produced Recombinant Protein Products
103
133
.
David C. Ream, Samuel T. Murakami, Emily E. Schmidt, Guo-Hua Huang, Chun Liang, Iddo Friedberg & Xiao-Wen Cheng. (2013) Comparative analysis of error-prone replication mononucleotide repeats across baculovirus genomes. Virus Research 178:2, pages 217-225.
Crossref
Crossref
Qinjian Zhao, Shaowei Li, Hai Yu, Ningshao Xia & Yorgo Modis. (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends in Biotechnology 31:11, pages 654-663.
Crossref
Crossref
Marieta McGrath, Gillian K. de Villiers, Enid Shephard, Inga I. Hitzeroth & Edward P. Rybicki. (2013) Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Archives of Virology 158:10, pages 2079-2088.
Crossref
Crossref
Amina I. Ahmed, Sara L. Bissett & Simon Beddows. (2013) Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines. Infection, Genetics and Evolution 18, pages 151-159.
Crossref
Crossref
Lin Zhang, Ronghong Tang, Shu Bai, Natalie K. Connors, Linda H. L. Lua, Yap P. Chuan, Anton P. J. Middelberg & Yan Sun. (2013) Molecular Energetics in the Capsomere of Virus-Like Particle Revealed by Molecular Dynamics Simulations. The Journal of Physical Chemistry B 117:18, pages 5411-5421.
Crossref
Crossref
Michele Pallaoro. 2013. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines
145
159
.
J. J. Smith, A. Burke, H. Bredell, W. H. van Zyl & J. F. Görgens. (2012)
Comparing cytosolic expression to peroxisomal targeting of the chimeric L1/L2 (
ChiΔH‐L2)
gene from human papillomavirus type 16 in the methylotrophic yeasts
Pichia pastoris
and
Hansenula polymorpha
. Yeast 29:9, pages 385-393.
Crossref
Crossref
Marianna FoldvariPraveen Kumar. (2012) Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection. Therapeutic Delivery 3:8, pages 1005-1017.
Crossref
Crossref
Gerrit Borchard, Farnaz Esmaeili & Simon Heuking. 2012. Chitosan‐Based Systems for Biopharmaceuticals. Chitosan‐Based Systems for Biopharmaceuticals
211
224
.
Marianna Foldvari. (2012) HPV infections: Can they be eradicated using nanotechnology?. Nanomedicine: Nanotechnology, Biology and Medicine 8:2, pages 131-135.
Crossref
Crossref
Cristian Speil & Robert Rzepka. (2011) Vaccines and Vaccine Adjuvants as Biological Response Modifiers. Infectious Disease Clinics of North America 25:4, pages 755-772.
Crossref
Crossref
Surender Khurana, Jian Wu, Nitin Verma, Swati Verma, Ramadevi Raghunandan, Jody Manischewitz, Lisa R. King, Eloi Kpamegan, Steven Pincus, Gale Smith, Gregory Glenn & Hana Golding. (2011) H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans. Journal of Virology 85:21, pages 10945-10954.
Crossref
Crossref
Hyoung Jin Kim, Hye-Lim Kwag, Yingji Jin & Hong-Jin Kim. (2011) The composition of the carbon source and the time of cell harvest are critical determinants of the final yield of human papillomavirus type 16 L1 protein produced in Saccharomyces cerevisiae. Protein Expression and Purification 80:1, pages 52-60.
Crossref
Crossref
Nathalie Garçon, Sandra Morel, Arnaud Didierlaurent, Dominique Descamps, Martine Wettendorff & Marcelle Van Mechelen. (2011) Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach. BioDrugs 25:4, pages 217-226.
Crossref
Crossref
Kate McKeage & Barbara Romanowski. (2011) Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†. BioDrugs 25:4, pages 265-269.
Crossref
Crossref
S. Capri, R. Gasparini, D. Panatto & N. Demarteau. (2011) Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology 121:3, pages 514-521.
Crossref
Crossref
Lawrence Segal, Owen K. Wilby, Chris R. Willoughby, Stéphane Veenstra & Marguerite Deschamps. (2011) Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. Reproductive Toxicology 31:1, pages 111-120.
Crossref
Crossref